Optimer Pharmaceuticals Sponsors ECCMID Symposium on Clostridium Difficile-Associated Disease: Current Treatments and Challenges
The educational symposium at the 18th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Barcelona, Spain, will compare current treatment options for CDI and highlight future therapies. The meeting titled, 'Clostridium difficile-Associated Disease: Current Treatments and Challenges' will also address the global and epidemic nature of this potentially fatal disease.
Experts participating in the symposium and their topics include:
-- Carl Erik Nord, M.D., Ph.D., Co-Chair of the symposium and Professor of Clinical Microbiology from the Department of Laboratory Medicine at the Karolinska University Hospital of the Karolinska Institute in Stockholm, Sweden - Introduction -- Ed Kuijper, M.D., Ph.D., Vice President of the European Society of Clinical Microbiology and Infectious Diseases and Professor of Medical Microbiology at the Leiden University Medical Centre in Leiden, the Netherlands - Clostridium Difficile - A Global Epidemic -- Frederic Barbut, Pharm.D., Ph.D., Infection Control Practitioner from the Infection Control Unit at Hopital Saint-Antoine in Paris, France - Infection Control and the prevention of CDAD -- Ian R. Poxton, Ph.D., DSc., Professor of Microbial Infection and Immunity at the University of Edinburgh College of Medicine and Veterinary Medicine in Edinburgh, Scotland - Risk Factors and Disease Severity: Implications for Treatment -- John G. Bartlett, M.D., Co-Chair of symposium and Professor of Medicine at the Johns Hopkins University of School of Medicine in Baltimore, Maryland - Current Treatments for CDAD: Successes and Failures -- Mark A. Miller, M.D., FRCPC., MSc., Chair of Infection Prevention and Control, Chief of the Division of Clinical Microbiology and Head of the Division of Infectious Diseases - Therapeutics in Development
CDI is a major concern within the international medical community due to the growing incidence, coupled with the spread of hypervirulent strains of Clostridium difficile responsible for more severe disease symptoms(2).
CDI is known to affect approximately 500,000 people in the U.S.(3) and is responsible for one in every 1,000 hospital admissions in Europe(4). CDI is a serious infection of the lining of the colon by Clostridium difficile bacteria, which in severe cases can result in death. Deaths from C. difficile (6,480) surpassed MRSA (1,650) in England and Wales in 2006.
"CDI remains a very serious health concern with increases in incidence and severity reported across the world. With the limitations of current therapies and limited clinical responses, there is a need for better therapeutic alternatives to treat CDI. Optimer is delighted to be working with leading global experts in meeting the challenges of CDI, and to inform ECCMID delegates about the latest advances," said Emmanuelle A. Hugentobler, M.D., Senior Director Medical Affairs, Optimer Pharmaceuticals. -0-
For further information/an invitation to this event please contact: Resolute Communications Optimer Pharmaceuticals, Inc. Con Franklin/Miranda Sykes Christina Donaghy +44 (0) 20 7015 1354 (858) 909-0736 ext. 154 +44 (0) 79 7443 4151 (cell) firstname.lastname@example.org email@example.com
Optimer Pharmaceuticals, Inc. (NASDAQ:OPTR), is a biopharmaceutical company focused on discovering, developing and commercializing innovative anti-infective products for the treatment of serious infections. Optimer has two late-stage anti-infective product candidates. OPT-80, currently in two pivotal Phase 3 clinical trials, is being developed for the treatment of Clostridium difficile infection, the most common hospital-acquired diarrhea. Prulifloxacin, also in two pivotal Phase 3 clinical trials, is an antibiotic being developed for the treatment of travelers' diarrhea, a form of infectious diarrhea. Additional information regarding Optimer can be found at http://www.optimerpharma.com
Statements included in this press release that are not a description of historical facts are forward-looking statements, including without limitation all statements related to incidence of CDI deaths associated with CDI, and anticipated symposia discussing CDI. Words such as "believes," "anticipates," "plans," "expects," "intend," "will," "goal" and similar expressions are intended to identify forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Optimer that any of its plans will be achieved. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Optimer's business including, without limitation, risks relating to: the timing, progress and likelihood of success of its product research and development programs, the timing and status of its preclinical and clinical development of potential drugs and other risks detailed in Optimer's filings with the Securities and Exchange Commission.
(1) ESGCD, September 2004 (2) McDonald LC, et al. (2005) "An epidemic, toxin gene-variant strain of Clostridium difficile". N Engl J Med 353: 2433-41. (3) Centers for Disease Control (4) "ESCMID Study Group Report: A European survey of diagnostic methods and testing protocols for Clostridium difficile", Clinical Microbiology and Infection, Vol. 9 Issue 10: 989, October 2003.
Optimer Pharmaceuticals, Inc.
(858) 909-0736 ext. 154
Con Franklin/Miranda Sykes
+44 (0) 20 7015 1354
+44 (0) 79 7443 4151 (cell)
Posted: April 2008